<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by BY on Medium]]></title>
        <description><![CDATA[Stories by BY on Medium]]></description>
        <link>https://medium.com/@booma.yandava?source=rss-0792a0c2d3a7------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*dmbNkD5D-u45r44go_cf0g.png</url>
            <title>Stories by BY on Medium</title>
            <link>https://medium.com/@booma.yandava?source=rss-0792a0c2d3a7------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 11:41:25 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@booma.yandava/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Looking Beyond the Brand: A Case for Escitalopram for Depression]]></title>
            <link>https://medium.com/@booma.yandava/looking-beyond-the-brand-a-case-for-escitalopram-for-depression-63467fb5cfa5?source=rss-0792a0c2d3a7------2</link>
            <guid isPermaLink="false">https://medium.com/p/63467fb5cfa5</guid>
            <dc:creator><![CDATA[BY]]></dc:creator>
            <pubDate>Fri, 23 May 2025 02:49:32 GMT</pubDate>
            <atom:updated>2025-05-23T02:58:58.085Z</atom:updated>
            <content:encoded><![CDATA[<p>Booma Yandava, Fellow, NPLB April, 2025 <a href="https://www.linkedin.com/in/booma/">Follow</a></p><p><strong>INTRODUCTION</strong></p><p>Escitalopram (specifically escitalopram oxalate for the salt form) is the generic version of Brand name drugs — Lexapro, primarily in the US and Cipralex, commonly used in Europe and other countries and is approved for the treatment of major depressive disorder (unipolar) in adults and adolescents (ages 12 to 17) for both acute and maintenance phases. The FDA recently approved escitalopram for the treatment of generalized anxiety disorder in both adults and children aged 7 and older. It is a S-enantiomer of the racemic drug citalopram. These drugs come under the class of selective serotonin reuptake inhibitor (SSRI). Escitalopram is also used off-label for conditions such as social anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, and the management of vasomotor symptoms associated with menopause.</p><p><strong>HISTORY</strong></p><p>The story of escitalopram begins with Lundbeck’s early interest in antidepressants in the 1960s when they launched Saroten®. This laid the foundation for their subsequent work that would eventually lead to the discovery of citalopram and later, the development of Cipramil®. Citalopram was developed first, with escitalopram being a later refinement. Research demonstrated that the S-enantiomer (escitalopram) was responsible for essentially all the serotonin reuptake inhibition, while the R-enantiomer was about 150 times less potent in inhibiting serotonin reuptake in rat brain synaptosome systems. Studies showed Escitalopram to be approximately 2 times more potent than citalopram and at least 40 times more potent than R-citalopram in inhibiting serotonin transporter functions</p><p><strong>PHARMACOLOGICAL PROPERTIES</strong></p><p>Escitalopram, (S)-1-[dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile 24 is the S-enantiomer of the racemic drug citalopram. As a selective serotonin reuptake inhibitor, Escitalopram is shown to be more potent than its racemate citalopram. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a crucial neurotransmitter that regulates various human behavioral processes, including mood, perception, memory, anger, aggression, fear, stress response, appetite, addiction, and sexuality. The expression of multiple serotonin receptors in brain regions, such as the cortex, limbic system, midbrain, and hindbrain, orchestrates these processes.[8] The brain has 5 primary serotonin receptors — 5-HT1A, 5-HT1B, 5-HT4, 5-HT6, and 5-HT7.[9] In total, there are 15 known serotonin receptors, which are also found outside the central nervous system.[8]</p><p><strong>DOSAGE AND ADMINISTRATION</strong></p><p>Escitalopram is administered orally and is available in 2 forms — an oral solution at a concentration of 1 mg/mL and tablets in 5 mg, 10 mg, or 20 mg strengths. It is highly recognized the need for personalized dosing, as the selection and adjustment of the dosage is to be tailored to the severity of depression, response to treatment and adult versus pediatric population.</p><p><strong>PATIENT IMPACT</strong></p><p>Escitalopram is one of the most widely prescribed antidepressants. As of 2022, it was the second most prescribed antidepressant and the fifteenth most prescribed medication overall in the United States, with more than 30 million prescriptions filled annually. In Australia, escitalopram consistently ranked among the top 10 most prescribed medications between 2017 and 2023. Major depressive disorder (MDD), for which escitalopram is primarily prescribed, has a lifetime prevalence of 10–20% in the general population. Recent estimates from 204 countries found that the global prevalence and burden of MDD increased by 27.6% in 2020 due to the COVID-19 pandemic. Recent estimates from 204 countries found that the global prevalence and burden of MDD increased by 27.6% in 2020 due to the COVID-19 pandemic.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/950/1*EPdf6omCN4SN5SyPNYFRlg.jpeg" /><figcaption>Fig: Global DALYs by mental disorder, sex, and age, 20191 Indicates depressive disorders ranking the highest in all ages DALYs=disability-adjusted life-years. Ref: <a href="https://doi.org/10.1016/">https://doi.org/10.1016/</a></figcaption></figure><p><strong>PRICING AND ACCESS</strong></p><p>The transition to generic escitalopram faced challenges from both regulatory and commercial perspectives. Forest Laboratories, the original manufacturer of brand-name Lexapro, experienced significant financial impact when escitalopram’s patent expired in March 2012. The company reported a net loss of $153.6 million in the fiscal quarter ending December 2012, with Lexapro’s sales plummeting 97% from almost $600 million to $20.3 million in that quarter.<br>There were legal battles surrounding escitalopram’s patent expiration. In July 2006, the U.S. District Court of Delaware ruled in favor of Lundbeck (the original developer) in a patent infringement dispute with Teva Pharmaceuticals, upholding the validity of escitalopram’s patent. Subsequently, Forest Laboratories received an 828-day extension on its U.S. patent, pushing the expiration date from December 2009 to September 2011, with a final expiration (including pediatric exclusivity) of March 14, 2012.<br>After patent expiration, multiple generic manufacturers entered the market, with Amneal Pharmaceuticals receiving approval for generic escitalopram oxalate on March 14, 2012. Currently, there are over 25 different manufacturers producing generic versions of escitalopram.</p><p><strong>BARRIERS TO ACCESS</strong></p><p>Access to mental health treatments like escitalopram faces several barriers. Insurance coverage is a significant factor, with a survey of psychiatric patients revealing that 61% of those not receiving mental health care cited cost as a barrier. Adults with mental illness have been shown to lack insurance coverage at significantly higher rates than those without mental illness.<br>High out-of-pocket costs can prevent patients from accessing needed medications. In a patient experience survey, 41% of patients taking prescription medicines reported at least one episode of non-adherence (not taking medicines as prescribed) in the past year. This rate was higher (52%) among patients in high-deductible health plans and particularly high (87%) among patients with outstanding medical debt.<br>Affordability presents a major barrier, especially for long-term medications like escitalopram that are often prescribed as part of a mix of different drugs. Many patients find it challenging to commit to the high costs of their medication regimens, particularly when they lack health insurance. While some medications might be affordable, others with higher costs may be avoided by patients with limited financial resources.<br>Beyond financial barriers, underserved communities face additional challenges in accessing mental health care, including lack of community-based interventions, unequal access to evidence-based practices, stigma, mental health workforce shortages, and geographical maldistribution of providers.</p><p><strong>TRUST IN GENERIC VERSIONS AND ACCESS IN UNDER SERVED COMMUNITIES</strong></p><p>There appears to be an issue of trust in generic versions of escitalopram, supported by some research findings. A nationwide study from Taiwan revealed that users of brand-name escitalopram had lower psychiatric hospitalization rates compared to those using generic products, which may influence both prescriber and patient preferences.<br>In underserved communities, the gap in mental health care access is particularly pronounced. Academic psychiatrists and other mental health leaders have identified three key strategies to reduce this treatment gap: increasing the number of mental health professionals, increasing the involvement of appropriately trained non-specialist providers, and actively involving people affected by mental disorders in care planning and delivery.<br>This comprehensive review highlights both the scientific aspects of escitalopram and the real-world challenges in ensuring its accessibility and effectiveness for patients who need it, particularly in underserved communities. The transition to generic availability has improved affordability for many, but barriers to access and concerns about equivalent effectiveness remain important considerations for both clinicians and health policy planners.</p><p><em>Note: This piece contributes to Public Domain Day for Generics, an initiative by No Patient Left Behind that promotes access to affordable medicines and raises awareness about the vital role of generics in improving healthcare accessibility. @NPLB @ElenaSolopova @NavdeepSinghBalla</em></p><p>REFERENCES<br>1. Mongelli F, Georgakopoulos P, Pato MT. Challenges and Opportunities to Meet the Mental Health Needs of Underserved and Disenfranchised Populations in the United States. Focus (Am Psychiatr Publ). 2020 Jan;18(1):16–24. doi: 10.1176/appi.focus.20190028. Epub 2020 Jan 24. PMID: 32047393; PMCID: PMC7011222.<br>2. Patel V: Global mental health: from science to action. Harv Rev Psychiatry 2012; 20:6–12 [DOI] [PMC free article] [PubMed] [Google Scholar]<br>3. National Center for Health Statistics. “Antidepressant Use Among Adults: United States, 2015–2018.” CDC, September 2020. (https://www.cdc.gov/nchs/data/databriefs/db377-H.pdf)<br>4. De Boer, H. (2012). Escitalopram (Cipralex®) — Patent litigation in Europe. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 9(3), 132–144. doi:10.1177/1741134312459647<br>5. Tsoutsanis, A. (2014). Finding Vredo (pat. pending): The Dutch Supreme Court Decision on ‘Escitalopram’ in Lundbeck v. Tiefenbacher et al. Journal of Intellectual Property Law &amp; Practice, 9(8), 644–649<br>6. Kesselheim, A.S., Misono, A.S., Shrank, W.H., et al. (2013). Variations in pill appearance of antidepressant drugs and the risk of nonadherence. JAMA Internal Medicine, 173(3), 202–208<br>7. Pereira VS, Hiroaki-Sato VA. A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatrica. 2018;30(6):307–322. doi:10.1017/neu.2017.39<br>8. https://www.fda.gov/media/135185/download<br>9. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/escitalopram-marketed-lexapro-information</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=63467fb5cfa5" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>